Quanterix Corp
A maker of ultra-sensitive blood tests and tissue-imaging tools for biology research and diagnostics. Its Simoa platform detects single protein molecules in blood, powering tests like LucentAD Complete for Alzheimer's disease, while its PhenoCycler spatial biology systems map proteins inside intact tissue. Founded in 2007 by scientist David Walt, whose lab invented the single-molecule array technology, the company began life as Digital Genomics before renaming itself Quanterix. Simoa is short for "single molecule array," and the firm grew further by acquiring spatial-biology pioneer Akoya Biosciences in 2025.
Granted 6.2K
Granted 6.7K
Granted 7.3K
Granted 4.3K
Bought 3.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Donnelly William PExecutive Chair, Director · 1 transaction | +2.2% | 154.1K | 6.2K | — | — |
| Miller Michael FrancisChief Technology Officer · 48 transactions | — | 33.9K | 6.7K | — | — |
| Sriram VandanaChief Financial Officer · 24 transactions | +20.4% | 31.6K | 7.3K | — | — |
| Mendel ScottDirector · 1 transaction | -76.8% | 12.5K | 4.3K | — | — |
| Meadows BenjaminChief Commercial Officer · 1 transaction | — | 3.5K | — | 3.5K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: +3.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.